International healthcare consultancy in health policy advisory, health technology assessment (HTA), investment planning. Graduated medicine, has MBA from AUBG, masters in public health, holds a PhD in HTA, completed executive education in Value measurement for healthcare (VMHC) at Harvard Business School. Teaches HTA, pharmacoeconomics, VMHC, co-author of >10 books on relevant topics and >90 scientific papers. For the last 6 years he’s managing HTA Ltd., with >600 analyses, >130 of them for orphan drugs, rare diseases; 19/20 top Pharma, 3/5 top medical devices companies. Since 2017 Dr. Djambazov has been active with health policy advisory and large health investment projects in Africa, Central and South East Asia.
Advertizing
